Thyrocare Technologies Limited has informed the Exchange regarding amendments to the Memorandum of Association of the Company.
THYROCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts more than Nifty Microcap 250 and 1.4 pts more than its Healthcare Service Provider peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Thyrocare's Board approved multiple items at its May 7, 2026 meeting. Key decisions include recommending a final dividend of Rs. 7 per share (total Rs. 9.33 per share for FY26 including interim dividend), appointing Price Waterhouse Chartered Accountants LLP as new statutory auditors for a 5-year term, and re-appointing Rahul Franklin Guha as Chairman, MD & CEO for another 5 years from May 2027. Two non-independent directors resigned (Dharmil Nirupam Sheth and Dr. Dhaval Rajesh Shah citing personal commitments), while two new directors (Uday Patel Kadam and Gaurav Verma) were appointed from API Holdings. The board also approved up to Rs. 5.5 crore equity investment in subsidiary Think Health Diagnostics and alterations to the MOA to align with the Companies Act, 2013 and expand business scope to include broader healthcare and diagnostics activities.
The resignation of two non-independent directors and appointment of two new directors from API Holdings signals potential board composition changes that investors should monitor. The MOA amendment broadening business scope and investment in subsidiary indicate expansion focus. The dividend payout provides near-term shareholder returns.